

Asthma Committee meeting 10

Date: 18/01/2023

Location: Virtual meeting

Minutes: Final

Committee members present:	
Lynn Eley	Present for notes 1-5
Matthew Doyle	Present for notes 1-5
Kevin Gruffydd-Jones	Present for notes 1-3
Stephen Fowler (Topic Adviser)	Present for notes 1-5
Natalie Harper	Present for notes 1-5
Sheba Joseph	Present for notes 1-5
Alan MacDonald (Co-Chair)	Present for notes 1-5
Kenneth Macleod	Present for notes 1-5
Andrew Molyneux (Co-Chair)	Present for notes 1-5
Elia Monterio	Present for notes 1-5
Kay Roy	Present for notes 1-5
Ian Sinha (Topic Adviser)	Present for notes 3-5
Colin Wilkinson	Present for notes 1-4
Edwina Wooler	Present for notes 1-5

In attendance:		
Amy Crisp	Senior Project Manager	Present for notes 1-5
Bernard Higgins	Clinical Director	Present for notes 1-5
Alfredo Mariani	Technical Analyst (Economics)	Present for notes 1-5
Toby Sands	Systematic Reviewer	Present for notes 1-5
Melina Vasileou	Senior Systematic Reviewer	Present for notes 1-5
Catriona Vernal	SIGN Programme	Present for notes 3-5

	Manager	
--	---------	--

Apologies:

Nick Staples

1. Welcome and objectives for the meeting

The Co-Chair welcomed the Committee members and attendees to the tenth Asthma guideline committee meeting.

The Co-Chair informed the Committee that apologies had been received, these are noted above.

The Co-Chair outlined the objectives of the meeting, which included: FeNO monitoring and drug combination and sequencing.

2. Confirmation of matter under discussion, and declarations of interest

The Co-Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were FeNO monitoring and drug sequencing.

The Co-Chair asked everyone to verbally declare any interests that have arisen since the last meeting. There were no new declarations of interest.

3. Evidence review

TS and AMa presented the following evidence review to the committee:

- 2.3 FeNO monitoring

The committee discussed the evidence presented.

4. Protocol

MV presented the following protocol to the committee:

- 3.2 Drug combination and sequencing

5. Any other business

- None.

Date of next meeting: 16/03/2023

Location of next meeting: Virtual meeting